Cemiplimab Clinical Trials
76 recruitingDrug
Phase 255Phase 125Phase 36
Showing 1–20 of 76 trials
Recruiting
Phase 1
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting
Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
Metastatic TumorSolid TumorLocally Advanced Solid Tumor
Mohammed Milhem35 enrolled1 locationNCT07404332
Recruiting
Phase 2
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
Sinonasal Squamous Cell CarcinomaStage III Sinonasal Cancer AJCC v8Stage IVA Sinonasal Cancer AJCC v8+1 more
National Cancer Institute (NCI)108 enrolled2 locationsNCT07281417
Recruiting
Phase 2
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Locally Advanced Adrenal Cortical CarcinomaMetastatic Adrenal Cortical CarcinomaRecurrent Adrenal Cortical Carcinoma+3 more
National Cancer Institute (NCI)48 enrolled67 locationsNCT06900595
Recruiting
Phase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Regeneron Pharmaceuticals220 enrolled52 locationsNCT06787612
Recruiting
Phase 2
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).
Locally Recurrent Oral Cavity Squamous Cell Carcinoma
M.D. Anderson Cancer Center17 enrolled1 locationNCT06448026
Recruiting
Phase 2
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Carcinoma in the Liver
City of Hope Medical Center11 enrolled1 locationNCT06860815
Recruiting
Phase 2
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell Carcinoma+15 more
National Cancer Institute (NCI)180 enrolled51 locationsNCT07195734
Recruiting
Phase 2
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
Colo-rectal Cancer
NSABP Foundation Inc79 enrolled1 locationNCT07058012
Recruiting
Phase 2
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Advanced Melanoma
Memorial Sloan Kettering Cancer Center88 enrolled12 locationsNCT06594991
Recruiting
Phase 2
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaStage III Laryngeal Cancer AJCC v8+19 more
National Cancer Institute (NCI)44 enrolled6 locationsNCT06980038
Recruiting
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
Non-small Cell Lung Cancer
Regeneron Pharmaceuticals500 enrolled49 locationsNCT05363319
Recruiting
Phase 1Phase 2
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
Stage IV Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma+2 more
National Cancer Institute (NCI)86 enrolled1 locationNCT07147231
Recruiting
Phase 1Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Endometrial CancerRecurrent Ovarian CancerLow Grade Serous Ovarian Cancer+3 more
Regeneron Pharmaceuticals890 enrolled52 locationsNCT03564340
Recruiting
Phase 2
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
Regeneron Pharmaceuticals120 enrolled10 locationsNCT06769698
Recruiting
Phase 2
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
Colorectal, Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins44 enrolled1 locationNCT06205836
Recruiting
Phase 2
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
Solid Tumors
M.D. Anderson Cancer Center40 enrolled1 locationNCT06651593
Recruiting
Phase 1
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
Prostate Cancer
M.D. Anderson Cancer Center60 enrolled1 locationNCT06826768
Recruiting
Phase 2Phase 3
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Stage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network378 enrolled386 locationsNCT06616584